Publications
- Postvaccination Immunogenicity of BNT162b2 SARS-CoV-2 Vaccine and Its Predictors in Pediatric Inflammatory Bowel Disease2023 | Second Faculty of Medicine
- Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study2022 | First Faculty of Medicine, Faculty of Physical Education and Sport, Second Faculty of Medicine
- Adalimumab versus infliximab in pediatric patients with Crohn's disease: A propensity-score analysis and predictors of treatment escalation2022 | Second Faculty of Medicine
- Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study2021 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Risk factors for dermatological complications of anti-TNF therapy in a cohort of children with Crohn's disease2021 | Second Faculty of Medicine
- Safety of Anti-TNF-Alpha Therapy During Pregnancy on Longterm Outcome of Exposed Children: A Controlled, Multicenter Observation2019 | First Faculty of Medicine, Second Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Pilsen
- Vedolizumab vs. Ustekinumab as second-line therapy in Crohn's disease in clinical practice2019 | First Faculty of Medicine
- Impact of anti-TNFα exposure in utero on the development of immune systems of exposed children - A controlled, multicentre observational study2018 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Pilsen, Third Faculty of Medicine
- Infliximab Biosimilar (Remsima (TM)) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre2017 | First Faculty of Medicine
- Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation2016 | First Faculty of Medicine, Second Faculty of Medicine
Loading network view...
